29 August 2014
New analysis of old HIV vaccines has identified something that could potentially protect immune response.
Researchers at Duke Medicine have reanalysed the findings of two historic paediatric HIV vaccine trials with encouraging results. `
The report, published in the Journal of Infectious Diseases, used fresh insights to examine the results from a recent adult HIV vaccine trial where the vaccine was found to reduce the number of infections by around 30 per cent.
This immune response was triggered by antibodies that attached to a specific region of the HIV virus's outer envelope, instead of broadly neutralising antibodies that have been considered vital for widespread vaccine success. However, this more specific antibody response was unknown when the original studies took place.
In the new analysis, the researchers retested the blood samples and found that infant HIV vaccination triggered the new immune response, with some participants still showing this response two years after.
Lead author Genevieve G. Fouda, assistant professor of paediatrics at Duke, said: "...The main goal is to prevent HIV transmission from mother-to-child during the period of breast feeding, inducing a two-year immunity would be long enough to be beneficial."
Posted by Jeanette Royston
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.